Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Preclinical
Recipient : Mithra Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Mithra Announces New Positive Preclinical Data from CSF-1R Inhibitor Program
Details : Colony-stimulating factor 1 receptor (CSF-1R) is a cell-surface tyrosine kinase receptor and a key regulator of macrophage biology and homeostasis andpromising therapeutic strategy for cancer treatment.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
June 15, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Preclinical
Recipient : Mithra Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Preclinical
Sponsor : Mithra Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Mithra acquired a purchase option on the rights to two development programs in innovative CSF1R kinase inhibitors, led by BCI Pharma. Under the terms of the contract, Mithra has the possibility to buy the rights to a development program on inhibitors.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
December 16, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Preclinical
Sponsor : Mithra Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Collaboration
Reset All
